<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vrachatis, Dimitrios A</style></author><author><style face="normal" font="default" size="100%">Papathanasiou, Konstantinos A</style></author><author><style face="normal" font="default" size="100%">Giotaki, Sotiria G</style></author><author><style face="normal" font="default" size="100%">Raisakis, Konstantinos</style></author><author><style face="normal" font="default" size="100%">Kossyvakis, Charalampos</style></author><author><style face="normal" font="default" size="100%">Kaoukis, Andreas</style></author><author><style face="normal" font="default" size="100%">Kolokathis, Fotis</style></author><author><style face="normal" font="default" size="100%">Deftereos, Gerasimos</style></author><author><style face="normal" font="default" size="100%">Iliodromitis, Konstantinos E</style></author><author><style face="normal" font="default" size="100%">Avramides, Dimitrios</style></author><author><style face="normal" font="default" size="100%">Bogossian, Harilaos</style></author><author><style face="normal" font="default" size="100%">Siasos, Gerasimos</style></author><author><style face="normal" font="default" size="100%">Giannopoulos, George</style></author><author><style face="normal" font="default" size="100%">Reimers, Bernhard</style></author><author><style face="normal" font="default" size="100%">Lansky, Alexandra</style></author><author><style face="normal" font="default" size="100%">Tardif, Jean-Claude</style></author><author><style face="normal" font="default" size="100%">Deftereos, Spyridon</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine.</style></title><secondary-title><style face="normal" font="default" size="100%">J Clin Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">J Clin Med</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 Oct 31</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">10</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">In 2020, SARS-COV-2 put health systems under unprecedented resource and manpower pressure leading to significant number of deaths. Expectedly, researchers sought to shed light on the pathophysiologic background of this novel disease (COVID-19) as well as to facilitate the design of effective therapeutic modalities. Indeed, early enough the pivotal role of inflammatory and thrombotic pathways in SARS-COV-2 infection has been illustrated. The purpose of this article is to briefly present the epidemiologic and clinical features of COVID-19, analyze the pathophysiologic importance of immunologic dysregulation and hypercoagulability in developing disease complications and finally to present an up-to-date systematic review of colchicine's immunomodulating capacity in view of hindering coronavirus complications.</style></abstract><issue><style face="normal" font="default" size="100%">21</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/34768648?dopt=Abstract</style></custom1></record></records></xml>